Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Copanlisib + Rituximab in relapsed indolent B-cell NHL
NCT02367040Phase 3Completed
- Sponsor
- Bayer
- Start
- Aug 2015
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 37
01
Overview
A Phase 3 trial of copanlisib in B-cell non-Hodgkin lymphoma (B-NHL), sponsored by Bayer. Started Aug 2015; status: completed.
02
Drugs
copanlisib
03
Conditions
B-cell non-Hodgkin lymphoma (B-NHL)
Beyond the preview
Go deeper on NCT02367040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02367040.